Detail akcie Beyond Air Rg online

Business Summary: Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
Financial Summary: BRIEF: For the six months ended 30 September 2025, Beyond Air Inc revenues increased from $1.5M to $3.6M. Net loss decreased 39% to $15.6M. Revenues reflect Beyond Air segment increase of 19% to $1.8M. Lower net loss reflects Research and development decrease of 48% to $4.9M (expense), Stock-based Compensation in SGA decrease of 50% to $2.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$10.99 to -$2.78.